Most ApoL1 is secreted by the liver

Journal of the American Society of Nephrology

Volumn 28, Issue 4, 2017, Pages 1079-1083

  Shukha, Khuloud ^a,b   Mueller, Jessica L ^b,c   Chung, Raymond T ^b,c   Curry, Michael P ^a,b   Friedman, David J ^a,b   Pollak, Martin R ^a,b   Berg, Anders H ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN L1; UNCLASSIFIED DRUG; APOL1 PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN;

ARTICLE; CADAVER DONOR; CLINICAL ARTICLE; CONTROLLED STUDY; GENOTYPE; GRAFT RECIPIENT; HUMAN; LIVER; LIVER GRAFT; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; BLOOD; GENETICS; LIVER TRANSPLANTATION; SECRETION (PROCESS);

APOLIPOPROTEINS; GENOTYPE; HUMANS; LIPOPROTEINS, HDL; LIVER; LIVER TRANSPLANTATION;

EID: 85021848663     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2016040441     Document Type: Article

References (16)

1. GenoveseG, Friedman DJ, RossMD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329: 841-845, 2010
2. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekele E, Bradman N, WasserWG, Behar DM, Skorecki K: Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128: 345-350, 2010
3. Behar DM, Kedem E, Rosset S, Haileselassie Y, Tzur S, Kra-Oz Z, Wasser WG, Shenhar Y, Shahar E, Hassoun G, Maor C, Wolday D, Pollack S, Skorecki K: Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population. Am J Nephrol 34: 452-459, 2011
4. Foster MC, Coresh J, Fornage M, Astor BC, Grams M, Franceschini N, Boerwinkle E, Parekh RS, Kao WH: APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 24: 1484-1491, 2013
5. Duchateau PN, Pullinger CR, Orellana RE, Kunitake ST, Naya-Vigne J, O'Connor PM, MalloyMJ, Kane JP: Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J Biol Chem 272: 25576-25582, 1997
6. Duchateau PN, Pullinger CR, ChoMH, EngC, Kane JP:Apolipoprotein L gene family: Tissuespecific expression, splicing, promoter regions; discovery of a new gene. J Lipid Res 42: 620-630, 2001
7. Weckerle A, Snipes JA, Cheng D, Gebre AK, Reisz JA, Murea M, Shelness GS, Hawkins GA, Furdui CM, Freedman BI, Parks JS, Ma L: Characterization of circulating APOL1 protein complexes in African Americans. J Lipid Res 57: 120-130, 2015
8. Cheng D, Weckerle A, Yu Y, Ma L, Zhu X, MureaM, Freedman BI, Parks JS, Shelness GS: Biogenesis andcytotoxicity ofAPOL1 renal risk variant proteins in hepatocytes and hepatoma cells. J Lipid Res 56: 1583-1593, 2015
9. Zhou H, Hoek M, Yi P, Rohm RJ, Mahsut A, Brown P, Saunders J, Chmielowski RA, Ren N, Shuster D, Southwick K, Ayanoglu G, Gorman D, Laface D, Santino S, Conway J, Liu Z, Cully D, Cleary M, Roddy TP, Blom D: Rapid detection and quantification of apolipoprotein L1 genetic variants and total levels in plasma by ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 27: 2639-2647, 2013
10. Kozlitina J, Zhou H, Brown PN, Rohm RJ, Pan Y, Ayanoglu G, Du X, Rimmer E, Reilly DF, Roddy TP, Cully DF, Vogt TF, Blom D, Hoek M. Plasma levels of risk-variant APOL1 do not associate with renal disease in a populationbased cohort. J Am Soc Nephrol 27: 3204-3219, 2016
11. Dorr CR, Freedman BI, Hicks PJ, Brown WM, Russell GB, Julian BA, Pastan SO, Gautreaux MD, Muthusamy A, Chinnakotla S, Hauptfeld V, Bray RA, Kirk AD, Divers J, Israni AK: Deceased-donor apolipoprotein L1 renal-risk variants haveminimal effects onliver transplant outcomes. PLoS One 11: E0152775, 2016
12. Freedman BI, Pastan SO, Israni AK, Schladt D, Julian BA, Gautreaux MD, Hauptfeld V, Bray RA, Gebel HM, Kirk AD, Gaston RS, Rogers J, Farney AC, Orlando G, Stratta RJ, Mohan S, Ma L, Langefeld CD, Bowden DW, Hicks PJ, Palmer ND, Palanisamy A, Reeves-Daniel AM, Brown WM, Divers J: APOL1 genotype and kidney transplantation outcomes from deceased African American donors. Transplantation 100: 194-202, 2016
13. Ma L, Shelness GS, Snipes JA, Murea M, Antinozzi PA, Cheng D, Saleem MA, Satchell SC, Banas B, Mathieson PW, Kretzler M, Hemal AK, Rudel LL, Petrovic S, Weckerle A, Pollak MR, Ross MD, Parks JS, Freedman BI: Localization of APOL1 protein and mRNA in the human kidney: Nondiseased tissue, primary cells, and immortalized cell lines. J Am Soc Nephrol 26: 339-348, 2015
14. Ito K, Bick AG, Flannick J, Friedman DJ, Genovese G, Parfenov MG, Depalma SR, Gupta N, Gabriel SB, Taylor HA Jr., Fox ER, Newton-Cheh C, Kathiresan S, Hirschhorn JN, Altshuler DM, Pollak MR, Wilson JG, Seidman JG, Seidman C: Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res 114: 845-850, 2014
15. Heneghan JF, Vandorpe DH, Shmukler BE, Giovinazzo JA, Raper J, Friedman DJ, Pollak MR, Alper SL: BH3 domain-independent apolipoprotein L1 toxicity rescued by BCL2 prosurvival proteins. Am J Physiol Cell Physiol 309: C332-C347, 2015
16. Lan X, Wen H, Saleem MA, Mikulak J, Malhotra A, Skorecki K, Singhal PC: Vascular smooth muscle cells contribute to APOL1-induced podocyte injury in HIV milieu. Exp Mol Pathol 98: 491-501, 2015